Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

5.420 +0.170 (+3.24%)

Streaming Delayed Price Updated: 11:49 AM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗

July 07, 2021

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...

Via Benzinga

The 6 Leading Psychedelic Stocks In Drug R&D ↗

July 07, 2021

Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D...

Via Talk Markets

Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market

July 07, 2021

Via FinancialNewsMedia

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies ↗

July 02, 2021

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...

Via Benzinga

Understanding Compass Pathways's Unusual Options Activity ↗

July 01, 2021

On Thursday, shares of Compass Pathways (NASDAQ:CMPS) saw unusual options activity. After the option alert, the stock price moved up to $38.2. Sentiment: NEUTRAL Option Type:...

Via Benzinga

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More ↗

June 30, 2021

Institutional analysts are taking a liking to the industry ...

Via Benzinga

3 Top Psychedelic Stocks to Buy Now ↗

June 30, 2021

These companies developing hallucinogens have more than meets the eye.

Via The Motley Fool

Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study ↗

June 29, 2021

Compass Pathways (NASDAQ:CMPS), a biotech company in the p...

Via Benzinga

Pandemic Fallout: 6 Mental Health Stocks To Watch ↗

June 28, 2021

One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 ↗

June 28, 2021

Upgrades For Toll Brothers Inc (NYSE:

Via Benzinga

Atai IPO Day An Underwhelming Event ↗

June 21, 2021

The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations.

Via Talk Markets

Topics Initial Public Offering

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform ↗

June 21, 2021

Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq...

Via Benzinga

Topics Artificial Intelligence

Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public ↗

June 18, 2021

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...

Via Benzinga

New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End ↗

June 18, 2021

Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO.

Via Investor's Business Daily

Topics Initial Public Offering

Is ATAI Stock A Buy After The IPO? ↗

June 16, 2021

ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock.

Via Talk Markets

Here's How This Psychedelic Drug CEO Sees The Industry Evolving ↗

June 09, 2021

Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said.

Via Investor's Business Daily

What Do You Really Know About Psychedelics And Psychedelics Stocks? ↗

June 08, 2021

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That...

Via Benzinga

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

June 08, 2021

Via FinancialNewsMedia

Topics Law Enforcement

Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York ↗

June 07, 2021

Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ...

Via Benzinga

Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price ↗

June 02, 2021

Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at...

Via Talk Markets

Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria ↗

May 28, 2021

As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producin...

Via Benzinga

Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week ↗

May 27, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week ↗

May 27, 2021

Welcome to the Cannabis...

Via Benzinga

Topics Cannabis

How Risky Are Psychedelic Stocks? ↗

May 26, 2021

Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder.

Via The Motley Fool

Topics Cannabis

Is Compass Pathways a Buy? ↗

May 25, 2021

The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker?

Via The Motley Fool

Topics Cannabis Law Enforcement

Can Psychedelics Actually Cure Depression and PTSD? ↗

May 25, 2021

There is now data suggesting that magic mushrooms and ecstasy -- combined with talk therapy -- may help people with severe depression and post-traumatic stress disorder.

Via The Motley Fool

Topics Cannabis

Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen ↗

May 20, 2021

MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline.

Via Investor's Business Daily

Compass Pathways Offers Chance on Exploratory Mental Health Treatments ↗

May 18, 2021

Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy.

Via InvestorPlace

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public ↗

May 17, 2021

Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...

Via Benzinga

Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts ↗

May 14, 2021

Compass Pathways (NASDAQ:CMPS), a company researching psyc...

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.